WebApr 11, 2024 · The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.90) by $1.00. The biotechnology company had revenue of $0.25 million for the quarter. Can-Fite BioPharma had a negative net margin of 1,379.68% and a negative trailing twelve-month return on equity of 103.11%. WebNov 25, 2024 · The decrease is primarily due to the decrease in professional services and public and investor relations expenses. We expect that general and administrative …
Can-Fite Reports 2024 Financial Results & Provides Clinical Update
WebAug 12, 2024 · Can-Fite BioPharma Ltd. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 5,000,000 of the Company’s American Depositary Shares WebMar 30, 2024 · Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the year ended December 31, 2024. 2024 & Recent Corporate and Clinical Development … impact investing climate change caribbean
Can-Fite BioPharm (NYSE American: CANF)
WebJan 9, 2024 · RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we … WebMar 30, 2024 · PETACH TIKVA, Israel, March 30, 2024 -- ( BUSINESS WIRE )-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule ... WebOct 11, 2012 · Can Fite BioPharma Ltd (CANF) Message Board - Company Name: Can Fite BioPharma Ltd, Stock Symbol: CANF, Industry: Biotechs - Total Posts: 1976 - Last … list software on pc